Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Condition:   Rhinitis, Allergic, Seasonal
Interventions:   Biological: MK-3641;   Biological: Placebo;   Drug: Self-injectable epinephrine;   Drug: Albuterol/Salbutamol;   Drug: Loratadine;   Drug: Olopatadine;   Drug: Mometasone furoate monohydrate
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting – verified June 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Primary Care Pathway for Childhood Asthma

Condition:   Asthma
Interventions:   Other: Primary care clinical pathway;   Other: Asthma education
Sponsors:   University of Alberta;   Alberta Innovates Health Solutions;   Alberta Health Services, Calgary;   Health Quality Council of Alberta (HQCA);   Southern Alberta Primary Care Research Network (SAPCReN);   Northern Alberta Primary Care Research Network (NAPCReN);   University of Calgary;   Ottawa Hospital Research Institute
Not yet recruiting – verified June 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days